Powell speech takes center stage in Tuesday’s economic events
BridgeBio Pharma NASDAQ:BBIO Chief Executive Officer Neil Kumar sold a total of 80,000 shares of common stock between October 8 and October 9, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The sales, executed under a prearranged Rule 10b5-1 trading plan, totaled $4.38 million. The transactions come as the stock trades near its 52-week high of $55.94, having delivered an impressive 122% return over the past year, according to InvestingPro data.
On October 8, Kumar sold 8,706 shares and 8,705 shares in two separate transactions at a weighted average price ranging from $53.82 to $54.81. Additionally, on the same day, he sold 11,294 shares and 11,295 shares in two separate transactions at a weighted average price ranging from $54.82 to $55.32 per share. On October 9, Kumar sold 20,000 shares in two transactions at a weighted average price ranging from $54.49 to $55.28. Based on InvestingPro’s Fair Value analysis, the stock appears slightly overvalued at current levels.
The shares were sold indirectly through the Kumar Haldea Revocable Trust and the Kumar Haldea Family Irrevocable Trust, of which Kumar is a co-trustee. Following the transactions, Kumar indirectly holds 5,494,133 shares and directly holds 223,090 shares of BridgeBio Pharma NASDAQ:BBIO. Get deeper insights into BridgeBio’s valuation, financial health, and growth prospects with InvestingPro’s comprehensive research report, which includes 12 additional exclusive ProTips.
In other recent news, BridgeBio Pharma has received positive attention from several investment firms due to its ongoing developments. UBS has maintained its Buy rating and increased its price target to $82.00, highlighting the company’s diversified late-stage portfolio and the upcoming Phase 3 data for encaleret, a promising treatment for Autosomal Dominant Hypocalcemia Type 1 (ADH1). Piper Sandler also reiterated an Overweight rating with a $68.00 price target, noting the strong launch dynamics of BridgeBio’s Attruby drug. The firm’s management expects third-quarter performance to mirror second-quarter trends concerning free-drug distribution and gross-to-net adjustments. H.C. Wainwright maintained its Buy rating, emphasizing the potential of encaleret, which addresses a genetic form of hypoparathyroidism. UBS further described ADH1 as a valuable asset in BridgeBio’s portfolio, which remains underappreciated. The company is also recognized for its increasing market share among new patient diagnoses, as noted by UBS. These developments reflect BridgeBio’s strategic focus on its key drug launches and its robust pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.